
Argenx stock jumps after positive Phase 3 trial results for new autoimmune myositis treatment.
Argenx reported successful Phase 3 clinical trial results for its drug VYVGART Hytrulo, targeting autoimmune myositis, especially benefiting patients with IMNM who lack approved therapies. The trial met its primary endpoint with statistically signifi...


